Celon Pharma S.A.

Warsaw Stock Exchange CLN.WA

Celon Pharma S.A. Price to Earnings Ratio (P/E) on January 14, 2025: -46.01

Celon Pharma S.A. Price to Earnings Ratio (P/E) is -46.01 on January 14, 2025, a -64.34% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Celon Pharma S.A. 52-week high Price to Earnings Ratio (P/E) is -26.07 on April 16, 2024, which is 43.33% above the current Price to Earnings Ratio (P/E).
Celon Pharma S.A. 52-week low Price to Earnings Ratio (P/E) is -61.49 on October 18, 2024, which is -33.67% below the current Price to Earnings Ratio (P/E).
Celon Pharma S.A. average Price to Earnings Ratio (P/E) for the last 52 weeks is -39.86.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Warsaw Stock Exchange: CLN.WA

Celon Pharma S.A.

CEO	Dr. Maciej Wieczorek Ph.D.
IPO Date	Feb. 17, 2017
Location	Poland
Headquarters	ul. Ogrodowa
Employees	566
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.

Key trends

Past 5 years